| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Belumosudil: First Approval
|
Blair, Hannah A.
|
|
|
81 |
14 |
p. 1677-1682
|
article
|
| 2 |
Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review
|
Elbers, Laura P. B.
|
|
|
81 |
14 |
p. 1645-1655
|
article
|
| 3 |
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
|
Neys, Stefan F. H.
|
|
|
81 |
14 |
p. 1605-1626
|
article
|
| 4 |
Comment on: “MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19”
|
Zhang, Song
|
|
|
81 |
14 |
p. 1691-1692
|
article
|
| 5 |
Correction to: Aducanumab: First Approval
|
Dhillon, Sohita
|
|
|
81 |
14 |
p. 1701
|
article
|
| 6 |
Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
|
Heo, Young-A
|
|
|
81 |
14 |
p. 1699
|
article
|
| 7 |
Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease
|
Hanzel, Jurij
|
|
|
81 |
14 |
p. 1697
|
article
|
| 8 |
Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat
|
Coats, Andrew J. S.
|
|
|
81 |
14 |
p. 1599-1604
|
article
|
| 9 |
Imeglimin Hydrochloride: First Approval
|
Lamb, Yvette N.
|
|
|
81 |
14 |
p. 1683-1690
|
article
|
| 10 |
Pharmacological Management of Acute Endodontic Pain
|
Khan, Asma A.
|
|
|
81 |
14 |
p. 1627-1643
|
article
|
| 11 |
Reply to Zhang and Zhu “MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19”
|
Ahmed, Nadine
|
|
|
81 |
14 |
p. 1693-1695
|
article
|
| 12 |
Savolitinib: First Approval
|
Markham, Anthony
|
|
|
81 |
14 |
p. 1665-1670
|
article
|
| 13 |
Telitacicept: First Approval
|
Dhillon, Sohita
|
|
|
81 |
14 |
p. 1671-1675
|
article
|
| 14 |
Tralokinumab: First Approval
|
Duggan, Sean
|
|
|
81 |
14 |
p. 1657-1663
|
article
|
Journal description